Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/27/1/49/16702043/mdv509.pdf
Reference59 articles.
1. Future directions and targeted therapies in bladder cancer;Sonpavde;Hematol Oncol Clin North Am,2015
2. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing failure with platinum-containing regimens;Bellmunt;J Clin Oncol,2010
3. Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials;Sonpavde;Eur Urol,2013
4. Improved 5-factor classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma;Sonpavde;J Urol,2015
5. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration;Liberati;PLoS Med,2009
Cited by 96 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Tislelizumab, a novel PD-1 monoclonal antibody in urothelial cancer: A real-world study;Actas Urológicas Españolas (English Edition);2023-12
2. Efficacy and Safety of Programmed Death-1/Programmed Death-Ligand 1 Inhibitor for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis;Current Oncology;2023-11-17
3. Progress in systemic therapy for advanced-stage urothelial carcinoma;Nature Reviews Clinical Oncology;2023-11-09
4. Tislelizumab, un nuevo anticuerpo monoclonal anti-PD-1 para el cáncer urotelial: estudio de vida real;Actas Urológicas Españolas;2023-11
5. Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma;Cancers;2023-08-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3